The court unanimously struck down a lawsuit seeking to restrict nationwide access to mifepristone, one of the two pills used in an abortion medication regimen. The court ruled that a group of doctors have no grounds to bring the lawsuit that sought to roll back the FDA's approval of mifepristone.
Medication abortion accounted for 63% of U.S. abortions in 2023 and its use is growing, becoming the most common form of abortion care in the U.S. The abortion pill regimen is the least expensive form of abortion care.
"The idea of limiting access to mifepristone will just further exacerbate disparities that we're already seeing in terms of reproductive health care," said Dr. Reshma Ramachandran, a family physician and health services researcher at Yale University School of Medicine.
[
add
]
[
|
|
...
]